NextCure, Inc. (NXTC) is a clinical-stage biopharmaceutical company that operates in the segment focused on discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Headquartered in Beltsville, Maryland, the company leverages its innovative proprietary platform, FIND-IO, to identify targets based on immunomodulatory function and direct applicability to cancer.
NextCure was established in 2015 by a team of accomplished scientists and biotechnology entrepreneurs; and in a short span of time, has grown significantly to make notable contributions to the field of oncology. The company's pipeline boasts several innovative approaches with distinct, promising immunotherapy candidates in various stages of preclinical and clinical development.
One of NextCure's key products, NC318, is currently in Phase 2 clinical development. NC318 is a first-in-class immunomedicine targeting Siglec-15, a novel immunomodulatory receptor expressed on a subset of myeloid cells in the tumor microenvironment in multiple types of cancer. In addition, it's developing NC410, an immune modulator designed to stimulate immune responses against cancer by blocking LAIR-1, an immune checkpoint that inhibits the activation of immune cells.
The company raised around $75 million in an initial public offering (IPO) in 2019. As of 2022, NextCure has established collaborations with leading pharmaceutical and biotechnology companies to augment and speed drug development. However, like all biotech firms, the company faces inherent risks involved with the drug development process, including safety, efficacy, regulatory hurdles, and commercial acceptance.
NextCure's mission is to discover and develop next-generation immunomedicines for patients with cancer and other diseases, using their proprietary FIND-IO platform to understand the complex interactions within the tumor microenvironment. This pursuit is defined by the company's steadfast commitment to innovation and improving patient outcomes. The progress NextCure has made is largely attributable to their platform's ability to identify novel targets, coupled with their industry-leading expertise in immuno-oncology. As NextCure continues to make strides in this challenging field, the hope is they can bring groundbreaking therapies to those in need.